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CASE REPORT
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This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar dis-
order receiving adjunctive tiagabine treatment. These defects were apparently reversible upon the discontinuation of tiagabine.
Controlled clinical trials are indicated to determine if this finding is indicative of a class effect for all GABAergic antiepileptic
drugs (AEDs), as already noted with vigabatrin, or if this case represents an incidental finding with tiagabine (41 references).
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INTRODUCTION
Visual field defects (VFDs) are a significant adverse
effect reported with the GABAergic antiepileptic drug
(AED) vigabatrin1, 2. In small studies, the prevalence
of VFDs has ranged from 40–83%, though most
often these defects were asymptomatic3–5. VFDs have
been reported to persist over time6, 7. Although most
studies to date do not show significant reversibility
of visual field loss, there are case reports that
suggest VFDs may be reversible if the vigabatrin
is withdrawn or lowered in dosage8, 9. Further,
even if the VFDs are not reversible, other visual
deficits (visual acuity / color vision / electroretinogram
changes) may be reversible10.
Vigabatrin is primarily an irreversible GABA-
transaminase inhibitor11. Vigabatrin also reduces
GABA re-uptake activity12. As a result, the GABA
levels in retinal cells are increased. It is thought that
vigabatrin induced VFDs are secondary to GABA
retinal toxicity3, 13, 14. If the defects are secondary to
increased GABA, does that mean that all AEDs with
similar mechanisms, increasing GABA levels, could
cause VFDs? Both diazepam and progabide have been
noted to cause VFDs, presumptively for the same
reason15, 16. It has been suggested that patients on
GABAergic AEDs (including vigabatrin, gabapentin,
topiramate, and tiagabine) require periodic visual field
evaluations or screening electroretinograms3, 14, 17–19.
Since these newer GABAergic AEDs are also utilized
in the treatment of bipolar disorders and pain
syndromes, the magnitude of the at-risk population
for VFDs is significantly greater than previously
thought20–23.
Tiagabine, in contrast to vigabatrin, causes in-
creased extracellular GABA by functioning as a re-
uptake inhibitor only24–26. Compared to vigabatrin,
the elevated GABA levels are lower and are not as
persistent. To date, there have been only four abstracts
published regarding the presence or absence of VFDs
with tiagabine treatment26–29.
This case represents the first patient treated with
adjunctive tiagabine for bipolar affective disorder who
developed VFDs that appear to have been reversible
after discontinuation of tiagabine.
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CASE REPORT
Clinical23
A 39-year-old white single male first presented in
1993 with a history of independent manic and depres-
sive episodes consistent with DSM-IV diagnoses of
bipolar affective disorder, alcohol abuse in remission,
and co-morbid panic disorder with agoraphobia30.
While being treated by a prior psychiatrist, he
was nonresponsive to lithium, had side effects with
nortriptyline, and was finally stabilized with total
daily doses of carbamazepine 1000 mg, trazodone
200 mg, perphenazine 4 mg, and benztropine 2 mg.
At time of initial assessment by this author in
1996, the patient had developed involuntary motor
movements. With discontinuation of perphenazine and
benztropine, these involuntary movements resolved.
All baseline blood chemistries, including thyroid
function tests, were within normal limits excluding
elevated triglycerides (512 mg dL−1), cholesterol
(217 mg dL−1) and GGT (417 IU L−1). MRI of the
brain and EEG were both normal. The carbamazepine
blood level was 9.9 ug ml−1. With development of
depressive features, trazodone was discontinued and
paroxetine was titrated to 40 mg daily with resolution
of these symptoms. After remaining stable for 1
year, the patient acutely developed significant manic
features (excessive spending / pressured speech / road
rage / marked irritability). In light of a history of
fatty liver disease associated with prior alcohol abuse
and persistently elevated GGTs (300s–400s), it was
not felt prudent to titrate the carbamazepine further
or to utilize valproate. Gabapentin was discontinued
after the patient developed ataxia and confusion. The
patient further regressed into a mixed bipolar state
with predominantly psychotic depressive features.
Use of clonazepam, lamotrigine and verapamil was
excluded secondary to an early history of poly-
substance abuse, a history of an allergic reaction
to verapamil, and the patient’s unwillingness to try
lamotrigine secondary to potential risks31, 32. The
rationale behind use of tiagabine, an AED without
prior literature in the treatment of bipolar disorders,
was explained to the patient in detail and he agreed
to utilize tiagabine adjunctively (1/9/98). Within 2
weeks on total daily doses of tiagabine 4 mg,
carbamazepine 1000 mg, and paroxetine 40 mg,
the patient showed dramatic improvement (euthymic
mood / no road rage / no hallucinations / minimal para-
noia / normal interest level / significant improvement
in sleep, appetite, and energy). Tiagabine was
titrated to 12 mg daily to maximize improvement
and within 1 month of initiation of tiagabine,
the patient denied the presence of any psychiatric
features.
The patient remained stable for >6 months on
tiagabine 8 mg daily, carbamazepine 1000 mg
daily, and paroxetine 40 mg daily after which an
unsuccessful attempt was made to gradually switch to
tiagabine monotherapy. Carbamazepine was reduced
to 600 mg daily, paroxetine to 10 mg daily, and
tiagabine was increased (based on re-emergence of
symptoms) to 32 mg daily. Ultimately the patient was
restabilized on tiagabine 12 mg daily, carbamazepine
600 mg daily, and paroxetine 20 mg daily. The
patient was unable to be maintained on this regimen
and a manic episode was precipitated by significant
work/travel related sleep deprivation. Olanzapine was
initiated at 7.5 mg daily with resolution of bipolar
features. At the same time, his neurologist prescribed
clonazepam 2 mg nightly for benign myoclonus.
When VFDs were noted on visual field evaluation,
tiagabine was discontinued (7/13/99) and low dose
topiramate was initiated (7/29/99). During his 18-
month exposure to tiagabine, his daily dose ranged
from 4–32 mg with an average daily dose of 13.2 mg.
The patient’s topiramate has been gradually increased
while maintaining affective stability. His present
psychotropic regimen includes total daily doses of
topiramate 125 mg, olanzapine 2.5 mg, carbamazepine
1000 mg, paroxetine 20 mg, and clonazepam 3 mg.
While under the care of this psychiatrist during the
past 3+ years, the patient has been on the following
other medications: amiloride, hydrochlorothiazide,
lisinopril, atorvastatin, orlistat, melatonin, rofecoxib,
ranitidine, beclomethasone dipropionate, albuterol,
fenofibrate, tramadol, allopurinal, and loratadine.
His non-psychiatric diagnoses include: hypertension,
hyperlipidemia, gout, hiatal hernia, gastroesophageal
reflux disorder, colitis, gallstones, fatty liver, sleep
apnea, fibromyalgia, obesity, and benign myoclonus.
Visual findings
In light of the increasing literature supporting
GABA based retinal toxicity associated with vi-
gabatrin, and the presumptive potential for other
GABAergic AEDs to have the same adverse side
effects, automated static threshold perimetry (Aller-
gan Humphrey 120-point full field screening test)
was obtained at 13 months [OD = 7/120 absolute
defects (AD); OS = 1/120 AD] and 18 months
[OD = 9/120 AD; OS = 6/120 AD] at which time
tiagabine was discontinued and topiramate was ini-
tiated. Post-discontinuation of tiagabine, Humphrey
VFs were obtained at 2 months [OD = 13/120 AD;
OS = 11/120 AD], 5 months [OD = 7/120 AD;
OS = 6/120 AD], 7.5 months [OD = 7/120 AD;
OS = 3/120 AD] and 16 months [OD = 8/120 AD;
OS = 3/120 AD]. These findings with relative
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Table 1: Allergan Humphrey 120-point computerized full field screening test.
2/11/99 7/13/99 9/20/99 12/22/99 3/1/00 11/8/00
OD TP 107/120 96/120 98/120 109/120 103/120 100/120
AD 7 9 13 7 7 8
RD 6 15 9 4 10 12
OS TP 119/120 102/100 97/120 108/120 111/120 111/120
AD 1 6 11 6 3 3
RD 0 12 12 6 6 6
TP = total points seen; AD = absolute defects; RD = relative defects.
 = POINTS SEEN: 97/120
 = RELATIVE DEFECTS: 12/120
 = ABSOLUTE DEFECTS: 11/120
 = BLIND SPOT
 = POINTS SEEN: 98/120
 = RELATIVE DEFECTS: 9/120
 = ABSOLUTE DEFECTS: 13/120
 = BLIND SPOT
60
Left Right
° 60 ° 60 ° 60 °
Fig. 1: Allergan Humphrey 120-point computerized full field screening test (9/20/99).
defects, absolute defects, and total points seen are
summarized in Table 1. Humphrey visual fields for the
maximal VFDs are represented in Fig. 1.
Central 40-point screening tests performed on this
patient in 1993 revealed 40/40 points seen OU.
VEPs performed after the patient was on tiagabine
for 11 months revealed an abnormal interocular
difference of 7.42 milliseconds. Repeat VEPs were
interpreted as normal with an interocular difference
of 1.5 milliseconds. An MRI with and without
gadolinium contrast was then performed and inter-
preted as normal.
Serial retinal and neuro-ophthalmologic evaluations
revealed ‘tiny’ macular drusen OU, mild retinal vein
tortuosity OU, unremarkable slit lamp examination
OU, normal intraocular pressures OU, fundus exam-
ination with slightly anomalous optic disc OU without
optic disc cup, and VFs normal to confrontation OU.
During the neuro-ophthalmolgic evaluation performed
on 3/30/00, Goldmann kinetic perimetry revealed
normal inner and outer isopters OU, American Optical
Hardy–Rand–Rittler (AOHRR) color plates were read
correctly 20 out of 20 OU, no central metamorphosia
was noted on Amsler grid OU though distortion was
reported at the grid edges OU, stereoacuity resolved
50 seconds of arc, mild color desaturation was noted
OS, and visual acuity was 20/20 OD and 20/15−1 OS
with correction.
DISCUSSION
This case report suggests the development of VFDs
associated with tiagabine adjunctive therapy that
improved with discontinuation of the tiagabine.
However, like most case studies, this report has
numerous limitations and cannot be generalized. The
most critical is that the patient did not have baseline
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visual fields or electroretinogram before receiving
tiagabine and was not rechallenged with tiagabine
to verify that the findings were causally related to
that specific AED. However, as a clinical case there
was insufficient data to support baseline evaluations
and ethical considerations precluded rechallenging
the patient with tiagabine. Confounding factors
include the patient’s multiple medical diagnoses and
chronic medications. It is not possible to state that
these played no role in the development of VFDs.
Specifically, visual abnormalities have been reported
with carbamazepine33, 34 and long-term usage may
have predisposed the patient to develop the VFDs
noted in this patient. Further, drug–drug interactions
may have played a significant role. For example, the
patient was initially on low dosage tiagabine while
receiving concomitantly the cytochrome P450 enzyme
inducer carbamazepine; however, later in the treatment
of this patient the tiagabine was increased to the
maximum daily dose of 32 mg with a reduced daily
dose of carbamazepine.
The initial worsening of VFDs OU during the first
2 months following discontinuation of tiagabine is
consistent with a toxic process that reaches maximal
effect before resolving. Although OS VFDs showed
consistent improvement from that point over the
course of treatment following tiagabine withdrawal,
the OD VFDs initially improved but most recently
showed gradual worsening. Is this post-tiagabine OD
finding related to underlying pathology, to his other
medications, or to a combination of both? This is
an important finding; for excluding withdrawal of
tiagabine and substitution with topiramate 15 months
ago (7/29/99; average daily dose = 75.64 mg), his
other medications have been stable over the course of
the past 3+ years. It has been suggested that other
GABAeric AEDs, including topiramate, may also be
causative for VFDs3, 16, 17, 19. If the potential etiology
is topiramate associated retinal toxicity, was it also
predisposed by the prior AED tiagabine?
Although the Goldmann perimetry was noted to
be normal (3/30/00), there are several possible ex-
planations: (1) Goldmann and Humphrey perimetries
are measured differently (the first is kinetic and
the second is static); (2) the patient had already
shown improvement in his VFDs when the Goldmann
perimetry was performed; (3) it has been reported that
in certain populations Humphrey perimetry detects
visual field loss before Goldmann perimetry35.
The severity of VFDs in this case is relatively mild
and the patient was asymptomatic. In this case, the
VFDs noted by automated static threshold perimetry
are best described as predominantly peripheral nasal
constriction in nature. However, temporal sparing
was present and one must wonder if the patient
had remained on tiagabine would the VFDs have
progressed to the more classic concentric VFDs
noted with vigabatrin in severe cases3, 6, 7, 36, 37.
Since tiagabine had been prescribed off-label for the
treatment of bipolar disorders, and further agents
(AEDs and atypical antipsychotics) are available,
ethical considerations mandated the discontinuation
of tiagabine in this case. Whether topiramate will be
discontinued in light of the recent gradual worsening
of the OD VFDs will depend on further visual field
evaluations.
Vigabatrin VFDs have been associated with daily
dose, total dose, and duration of treatment5, 13, 38–40.
Whether this will be true with tiagabine or other
GABAergic AEDs can only be determined with
VF and electroretinogram evaluations in controlled
clinical studies. The VFDs can be asymptomatic
for years and VFs by confrontation or questionnaire
cohort studies are not considered to be sufficient40, 41.
A summary of potential factors needing to be
addressed in tiagabine VFDs, or those associated
with other AEDs, include: total dose, maximal dose,
rapidity of titration to maximum dosage, drug–drug
interactions or cumulative effect upon retinal GABA
levels secondary to other pharmaceuticals / genetic
predisposition / selective vulnerability / other underly-
ing pathology.
In light of the progression of VFDs over time, it
is recommended that potential causative (GABAergic)
AEDs have baseline VFs and electroretinograms with
serial evaluations every 6–8 months. If VFDs are
noted, the dosage of the AED should be decreased
to determine if VFDs improve or stabilize. Since
these VFDs are usually asymptomatic, continuation
of the AED should be based on clinical necessity. If
significant VFDs are noted when the AED is being
used for off-label purposes, as in the treatment for
bipolar disorders wherein other agents are available,
ethical considerations mandate discontinuation of the
AED. If the patient cannot be stabilized on alternative
agents, then the AED should be re-initiated with
detailed consent.
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